dc 015 has been researched along with ketanserin in 1 studies
*Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients. [MeSH]
*Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients. [MeSH]
| Studies (dc 015) | Trials (dc 015) | Recent Studies (post-2010) (dc 015) | Studies (ketanserin) | Trials (ketanserin) | Recent Studies (post-2010) (ketanserin) |
|---|---|---|---|---|---|
| 7 | 0 | 0 | 3,094 | 335 | 283 |
| Protein | Taxonomy | dc 015 (IC50) | ketanserin (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.0016 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0021 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.015 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 0.015 | |
| 5-hydroxytryptamine receptor 1D | Homo sapiens (human) | 0.265 | |
| 5-hydroxytryptamine receptor 1B | Homo sapiens (human) | 6.5 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.0184 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.0027 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.0016 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.29 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.015 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 1.8 | |
| Synaptic vesicular amine transporter | Homo sapiens (human) | 0.18 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.001 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, CH; Chern, JW; Chien, SL; Lai, YJ; Lu, GY; Shiau, CY; Tao, PL; Yen, MH | 1 |
1 other study(ies) available for dc 015 and ketanserin
| Article | Year |
|---|---|
Studies on quinazolines. 5. 2,3-dihydroimidazo[1,2-c]quinazoline derivatives: a novel class of potent and selective alpha 1-adrenoceptor antagonists and antihypertensive agents.
Topics: Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Binding, Competitive; Blood Pressure; Quinazolines; Rats; Rats, Inbred SHR; Structure-Activity Relationship | 1993 |